Comparison of Central Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter and Central Venous Catheter
Launched by MESPERE LIFESCIENCES INC. · Feb 7, 2013
Trial Information
Current as of April 30, 2025
Unknown status
Keywords
ClinConnect Summary
The conventional bedside pulse oximeter has been a standard in clinical care for non-invasive hemodynamic monitoring and measures arterial blood oxygenation. To date, a non-invasive bedside monitor for measuring mixed venous oxygen saturation (SvO2) has not been developed. The clinical applications of venous oximetry are numerous and include management of severe sepsis and septic shock, trauma and hemorrhagic shock, heart failure and cardiac arrest.
The existing method for venous blood oxygenation monitored is either through an invasive fiber optic catheter, or intermittently by blood samp...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 and older
- • Patients admitted to the ICU
- • Patients who have or are scheduled to have an indwelling central venous catheter inserted via the internal jugular vein or subclavian vein as part of their usual care
- Exclusion Criteria:
- • Abnormal neck anatomy
- • Unable to identify jugular vein under ultrasound guidance
- • Allergic to adhesive tape
- • Presence of known anatomical shunt or AV dialysis fistula
- • Known central vein stenosis
About Mespere Lifesciences Inc.
Mespere Lifesciences Inc. is a pioneering clinical trial sponsor focused on advancing innovative therapeutic solutions in the fields of neurology and pain management. With a commitment to enhancing patient outcomes through rigorous research and development, Mespere leverages cutting-edge technologies and a collaborative approach to bring novel treatments from the laboratory to clinical practice. The company prioritizes ethical standards and regulatory compliance, ensuring that all trials are conducted with the highest level of integrity and scientific rigor. Through its dedication to addressing unmet medical needs, Mespere Lifesciences aims to transform the landscape of healthcare and improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, Ontario, Canada
Patients applied
Trial Officials
Michael Sharpe, MD, FRCPC
Principal Investigator
LHSC University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials